ClinicalTrials.gg
TerminatedNCT02494778Open PRIDE-HDUpdated Sep 17, 2021Results posted

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

A Phase 2 interventional study of Pridopidine in Huntington's Disease, sponsored by Prilenia. Terminated at 46 sites in 11 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by Prilenia · Phase 2, Interventional, and Treatment

Why this study was terminated
This study served its purpose in providing considerable safety data.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
248
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Enrollment
15th of 90
248 · median 44
Started
2015
with 3 others
Phase 2
28 of 138
none open now
Registered
66th of 138
by date
Lead sponsor
4 of 138
Prilenia

Among the 138 studies in Huntington Disease with a site in United States, this one is the 15th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2015, is one of 28 in phase 2, and was the 66th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).

03

Conditions studied

  • Huntington's Disease

Browse trials for

Keywords

  • Huntington's disease, pridopidine
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pride HD completion within the last 6 months, including 2 week follow up period or patients who transitioned from the Open HART study or patients who complete future safety and efficacy clinical trials of pridopidine. In addition, patients who have already completed their defined study period under Open PRIDE HD global or local amendments and have discontinued treatment with pridopidine will be allowed to re enter the Open PRIDE HD study.
  • Women of child bearing potential or male participants: Adequate and birth control
  • Good general health

    • other criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Similar baseline criteria for , vital signs, cardiovascular system, and renal function to PRIDE HD;
  • Similar concomitant medication restrictions to PRIDE HD.

    • other criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Pridopidine

    The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.

    Drug: Pridopidine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    From signature of the informed consent form through the end of the study, which was defined as Week 106

    Time frame: 106 weeks

Secondary outcomes

  1. Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand

    Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Onset-interval-SD-Hand, measured in seconds. Positive change from baseline indicates worsening.

    Time frame: Week 52; end of treatment (EOT) which was planned to occur at Week 104

  2. Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand

    Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Peak-Force-CV-Hand, measured in %. Positive change from baseline indicates worsening.

    Time frame: Week 52; end of treatment (EOT) which was planned to occur at Week 104

07

Results

Posted Sep 17, 2021
Limitations and caveats
This was an open-label extension of study TV7820-CNS-20002. It was terminated on 10 Nov 2017, as it was considered by the sponsor to have served its purpose in providing long-term safety data. Study termination was not based on safety concerns.

Participant flow

Participant flow — Overall Study
MilestonePridopidine 45 mg BID
Started248
Completed27
Not completed221
Withdrew: Death3
Withdrew: Other173
Withdrew: Lack of efficacy4
Withdrew: Adverse event18
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up2
Withdrew: Noncompliant with study drug admin.1

Outcome measures

PrimaryPercentage of Participants With Adverse Events

From signature of the informed consent form through the end of the study, which was defined as Week 106

Time frame:
106 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events
ParticipantsPridopidine 45 mg BID
Percentage of Participants With Adverse Events193
SecondaryChange From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand

Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Onset-interval-SD-Hand, measured in seconds. Positive change from baseline indicates worsening.

Time frame:
Week 52; end of treatment (EOT) which was planned to occur at Week 104
Reported as:
Mean · second
Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand
secondPridopidine 45 mg BID
Change from baseline to Week 520.0 ± 0.05
Change from baseline to EOT-0.1 ± 0.01
SecondaryChange From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand

Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Peak-Force-CV-Hand, measured in %. Positive change from baseline indicates worsening.

Time frame:
Week 52; end of treatment (EOT) which was planned to occur at Week 104
Reported as:
Mean · percentage
Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand
percentagePridopidine 45 mg BID
Change from baseline to Week 52-2.9 ± 9.31
Change from baseline to EOT-5.9 ± 8.05

Adverse events

Collected over From signature of the informed consent form through the end of the study, which was defined as Week 106. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pridopidine 45 mg BID3/248 (1.2%)31/248 (12.5%)191/248 (77%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventPridopidine 45 mg BID
FallInjury, poisoning and procedural complications4/248
Suicidal ideationPsychiatric disorders3/248
ChoreaNervous system disorders3/248
Subdural haematomaInjury, poisoning and procedural complications2/248
PneumoniaInfections and infestations2/248
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/248
Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/248
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/248
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/248
DeathGeneral disorders1/248
Most frequent other events
Most frequent other events
EventPridopidine 45 mg BID
FallInjury, poisoning and procedural complications74/248
NasopharyngitisInfections and infestations29/248
ChoreaNervous system disorders23/248
InsomniaPsychiatric disorders20/248
AnxietyPsychiatric disorders16/248
HeadacheNervous system disorders14/248
Back painMusculoskeletal and connective tissue disorders14/248
ContusionInjury, poisoning and procedural complications13/248
Weight decreasedInvestigations13/248

Baseline characteristics

Enrolled patients

Age, Continuous
Age, Continuous(years)Pridopidine 45 mg BID
Mean50.6 ± 11.61
Sex: Female, Male
Sex: Female, Male(Participants)Pridopidine 45 mg BID
Female129
Male119
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pridopidine 45 mg BID
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White227
More than one race0
Unknown or Not Reported19
Region of Enrollment
Region of Enrollment(participants)Pridopidine 45 mg BID
Canada4
Austria18
Netherlands9
United States34
Poland28
Italy34
United Kingdom28
France18
Australia9
Germany32
Russia34
CYP2D6 metaboliser genotype
CYP2D6 metaboliser genotype(Participants)Pridopidine 45 mg BID
Poor metaboliser8
Extensive metaboliser214
Intermediate metaboliser25
Ultra-rapid metaboliser1
Neuroleptic use
Neuroleptic use(Participants)Pridopidine 45 mg BID
Yes94
No154
Number of CAG repeats
Number of CAG repeats(CAG repeats)Pridopidine 45 mg BID
Mean44.8 ± 4.01
08

Study locations

46 sites
  • Teva Investigational Site 12204
    Los Angeles, California 90095, United States
  • Teva Investigational Site 12201
    Englewood, Colorado 80113, United States
  • Teva Investigational Site 12196
    Washington, District of Columbia 20007, United States
  • Teva Investigational Site 12206
    Baltimore, Maryland 21287, United States
  • Teva Investigational Site 12200
    Manhasset, New York 11030, United States
  • Teva Investigational Site 12203
    New York, New York 10032, United States
  • Teva Investigational Site 12198
    Rochester, New York 14618, United States
  • Teva Investigational Site 12211
    Winston-Salem, North Carolina 27157, United States
  • Teva Investigational Site 12209
    Pittsburgh, Pennsylvania 15213, United States
  • Teva Investigational Site 12208
    Salt Lake City, Utah 84108, United States
  • Teva Investigational Site 12210
    Richmond, Virginia 23230, United States
  • Teva Investigational Site 78055
    Caulfield South, 3162, Australia
  • Teva Investigational Site 78058
    West Perth, 6005, Australia
  • Teva Investigational Site 78057
    Westmead, 2145, Australia
  • Teva Investigational Site 33021
    Innsbruck, A-6020, Austria
  • Teva Investigational Site 33027
    Wien, 1010, Austria
  • Teva Investigational Site 11036
    Toronto, Ontario M3B 2S7, Canada
  • Teva Investigational Site 35123
    Angers cedex 9, 49933, France
  • Teva Investigational Site 35122
    Creteil, 94010, France
  • Teva Investigational Site 35125
    Lille Cedex, 59037, France
  • Teva Investigational Site 35124
    Marseille Cedex 5, 13385, France
  • Teva Investigational Site 35121
    Salouel, 80054, France
  • Teva Investigational Site 35165
    Toulouse, 31059, France
  • Teva Investigational Site 32408
    Berlin, 10117, Germany
  • Teva Investigational Site 32410
    Bochum, 44791, Germany
  • Teva Investigational Site 32409
    Munster, 48149, Germany
  • Teva Investigational Site 32407
    Ulm, 89081, Germany
  • Teva Investigational Site 30083
    Firenze, 50134, Italy
  • Teva Investigational Site 30080
    Milano, 20133, Italy
  • Teva Investigational Site 30082
    Napoli, 80131, Italy
  • Teva Investigational Site 30081
    San Giovanni Rotondo, 71013, Italy
  • Teva Investigational Site 38059
    Leiden, 2333 ZA, Netherlands
  • Teva Investigational Site 53150
    Gdansk, 80-462, Poland
  • Teva Investigational Site 53149
    Krakow, 31-505, Poland
  • Teva Investigational Site 53148
    Poznan, 60-529, Poland
  • Teva Investigational Site 53151
    Warsaw, 02-957, Poland
  • Teva Investigational Site 50215
    Kazan, 420101, Russian Federation
  • Teva Investigational Site 50213
    Moscow, 125367, Russian Federation
  • Teva Investigational Site 50214
    Nyznij Novgorod, 603126, Russian Federation
  • Teva Investigational Site 34058
    Birmingham, B15 2SG, United Kingdom
  • Teva Investigational Site 34054
    Cambridge, CB2 2PY, United Kingdom
  • Teva Investigational Site 34059
    Cardiff, CF14 4XN, United Kingdom
  • Teva Investigational Site 34055
    Manchester, M13 9WL, United Kingdom
  • Teva Investigational Site 34061
    Newcastle-Upon-Tyne, NE6 4QD, United Kingdom
  • Teva Investigational Site 34056
    Oxford, OX3 9DU, United Kingdom
  • Teva Investigational Site 34057
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Cohen S, Waks Z, Elm JJ, Gordon MF, Grachev ID, Navon-Perry L, Fine S, Grossman I, Papapetropoulos S, Savola JM. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease. BMC Med Inform Decis Mak. 2018 Dec 20;18(1):138. doi: 10.1186/s12911-018-0714-7. PubMed 30572891 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Jan 2018, 27 months.

Results were first posted in Sep 2021, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2015
First posted
Jul 10, 2015
StartActual
Sep 24, 2015
Primary completionActual
Jan 12, 2018
CompletionActual
Jan 12, 2018
Results first posted
Sep 17, 2021
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02494778
Lead sponsor
Prilenia
Responsible party
Sponsor
First posted
Jul 10, 2015
Start date
Sep 24, 2015
Primary completion
Jan 12, 2018
Completion
Jan 12, 2018
Results posted
Sep 17, 2021
Last update
Sep 17, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Pharmaceuticals USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion